Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 1997

View Archived Issues

DepoTech: Q3 1997 highlights

Penwest: Q4 and FY 1997 highlights

Kyowa Hakko: Annual Report 1997

Tripos: Q3 1997 highlights

Antitumor effects of Techniclone's LYM-2 reported

FDA clears generic estradiol product

Lilly and Chugai enter into combinatorial chemistry collaboration

Apligraf comparable to autograft for donor site wounds

Diester prodrugs of antiviral acyclic nucleoside disclosed by Medivir

Biomeasure discloses protein farnesyltranserase inhibitors

Endothelin antagonists described by Bristol-Myers Squibb

New serine protease inhibitors for thrombotic disorders from Akzo Nobel

Shionogi presents potent and selective CCKB/gastrin receptor antagonist

Effects of NO donor ITF-1129 on blood flow/hemodynamics during myocardial ischemia

Advisory committee recommends approval for Plavix

Banyu discloses protein farnesyltransferase inhibitors

New ACAT inhibitors discovered at Mitsubishi Chemical

Update on Sano product pipeline

Pravachol now available in Canada for preventing a first heart attack

Differin is equieffective but better tolerated than Retin A in patients with acne

Bicalutamide + LHRH-A vs. flutamide + LHRH-A for metastatic prostate cancer

Hepatitis C-related technology available for licensing from NIH

Lyme disease diagnostic technology available for licensing

MuLV diagnostic kit available from NIH

FDA clears generic cimetidine

Gene therapy approach to preventing organ transplant complication explored

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...